Clorox stock hits 52-week low at 120.68 USD

Clorox (CLX) recently hit a 52-week low of $120.68 amid a challenging year, with the stock down 11.62% over the past 12 months, despite maintaining a 4% dividend yield and 48 years of dividend increases. Fiscal third-quarter earnings missed expectations, with an EPS of $1.45 and a 2% decline in organic sales, although gross margin increased by 240 basis points to 44.6%; analysts from Jefferies, Wells Fargo, and JPMorgan have adjusted price targets, reflecting concerns over organic sales growth and the broader environment for home and personal care, while Clorox appointed Gina Boswell to its board of directors.

Analysis

Clorox Co. (CLX) has recently experienced significant stock price pressure, hitting a 52-week low of $120.68 and marking an 11.62% decline over the past year. Despite this, the company maintains a robust 4% dividend yield and an impressive 48-year history of consecutive dividend increases. Recent fiscal third-quarter results presented a mixed picture: earnings per share (EPS) of $1.45 missed consensus estimates from Raymond James and others, and organic sales saw a 2% year-over-year decline, falling short of flat growth expectations. However, Clorox demonstrated resilience in profitability, with its gross margin expanding by 240 basis points to 44.6%, exceeding various analysts’ expectations; the company also reports a general gross profit margin of 45%. Management has adjusted its fiscal year 2025 organic sales growth forecast to 4-5%, which notably includes an anticipated 2-3 percentage point contribution from a sales pull-forward. Reflecting these headwinds, multiple analysts have revised their price targets downwards: Jefferies to $167 (maintaining a Buy), Wells Fargo to $142 (Equal Weight), and JPMorgan to $144 (Neutral), citing the organic sales miss and a challenging environment for the Home and Personal Care sector. InvestingPro analysis suggests the stock is in oversold territory based on its RSI and is potentially undervalued, with positive earnings forecasts also noted. Strategically, Clorox is strengthening its board with the appointment of Gina Boswell, CEO of Bath & Body Works, effective May 19, 2025, bringing extensive consumer goods experience.

Key Decisions for Investors

• Investors should weigh the attractive 4% dividend yield and 48-year dividend growth history against the recent 11.62% stock decline and Q3 operational challenges, including the 2% organic sales decrease and EPS miss.
• The stock's attainment of a 52-week low and an oversold RSI, coupled with InvestingPro's undervaluation assessment, may present a tactical entry point for value-oriented investors, though confirmation of sustained organic sales recovery towards the guided 4-5% for FY25 is crucial.
• Closely monitor the execution of Clorox's strategic adjustments, the impact of new board member Gina Boswell, and upcoming financial reports for signs of a fundamental turnaround in the face of current market pressures and sector-specific headwinds.